NCT06122506

Brief Summary

Every year 15 million babies are born prematurely, which can lead to death or life-long disabilities. It is often caused by a dysfunction of the uterine cervix, which constitutes the narrow channel between the vagina and womb. During pregnancy, this channel must remain closed until the beginning of term labor. A weak cervix may not withstand the weight of the fetus, the amniotic fluid and the placenta and the cervical canal will open and cause late miscarriage or preterm delivery. To prevent this, a band (cerclage) can be applied around the cervix either vaginally or laparoscopically prior to a new pregnancy. To evaluate which treatment is best for most women, we will randomize (allocate by chance) women at risk for preterm birth, to either vaginal cerclage or laparoscopic cerclage in the Nordic countries and England

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
188

participants targeted

Target at P75+ for not_applicable

Timeline
22mo left

Started Jan 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Jan 2024Mar 2028

First Submitted

Initial submission to the registry

November 3, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 8, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

January 31, 2024

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Last Updated

December 10, 2024

Status Verified

September 1, 2024

Enrollment Period

3.8 years

First QC Date

November 3, 2023

Last Update Submit

December 5, 2024

Conditions

Keywords

cerclage

Outcome Measures

Primary Outcomes (2)

  • Delivery <32+0 weeks of gestation.

    In the first subsequent viable pregnancy beyond 14+0 weeks of gestation. First prioritized primary outcome.

    At birth.

  • Baby death.

    Loss of a viable pregnancy beyond 14+0 weeks of gestation, miscarriage, stillbirth or death of a live born infant. Second prioritized primary outcome.

    From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation.

Secondary Outcomes (32)

  • Maternal mortality - surgery related.

    30 days after insertion of laparoscopic or vaginal cerclage.

  • Maternal mortality.

    From time of randomisation - 42 days after delivery.

  • Maternal morbidity - surgery related.

    30 days after insertion of laparoscopic or vaginal cerclage.

  • Maternal morbidity

    From time of randomisation - 42 days after delivery.

  • Harm to participant - surgery related.

    30 days after insertion of laparoscopic or vaginal cerclage.

  • +27 more secondary outcomes

Study Arms (2)

Intervention

EXPERIMENTAL

Laparoscopic cerclage

Procedure: Laparoscopic cerclage

Control

EXPERIMENTAL

Vaginal cerclage

Procedure: Vaginal cerclage

Interventions

Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.

Also known as: Abdominal cerclage
Intervention

Transvaginal cerclage in pregnant women.

Control

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsEligibility based on biologic sex.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women in whom the clinician has equipoise as to whether an elective vaginal or abdominal cerclage will be the best intervention to prevent preterm birth.
  • Not yet pregnant or \<10 weeks' pregnant.

You may not qualify if:

  • Any condition or circumstance under which laparoscopic or vaginal cerclage surgery is contraindicated (i.e. on-going pregnancy of more than 10+0 gestational weeks).
  • Language difficulties.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aarhus University Hospital

Aarhus N, Denmark

RECRUITING

Rigshospitalet

Copenhagen, Denmark

RECRUITING

Related Publications (1)

  • Hansen LK, Krogh LQ, Lantto A, Uldbjerg N, Jensen PT, Shennan A, Hald K, Heikinheimo O, Jacobsson B, Hjartardottir H, Karypidis H, Glavind J. Nordic randomised trial on laparoscopic versus vaginal cerclage (NORACT): trial protocol for an international, multicentre, randomised controlled trial. BMJ Open. 2025 Sep 23;15(9):e107093. doi: 10.1136/bmjopen-2025-107093.

Related Links

MeSH Terms

Conditions

Premature BirthUterine Cervical Incompetence

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesAbortion, HabitualAbortion, SpontaneousGenital Diseases

Study Officials

  • Niels Uldbjerg, DMSc

    Aarhus University Hospital

    STUDY DIRECTOR
  • Julie Glavind, MD, PhD

    Aarhus University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lea K Hansen, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 2023

First Posted

November 8, 2023

Study Start

January 31, 2024

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

March 1, 2028

Last Updated

December 10, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will share

After publication of the trial results, the final dataset will be publicly available in an anonymized form using i.e. Zenodo open data repository (CERN) or another equivalent database.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning three months and ending three years after the publication of the last trial results.
Access Criteria
Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the NORACT Board depending on the nature of their involvement.

Available IPD Datasets

Statistical Analysis Plan Access
Study Protocol Access

Locations